Skip to main content
Top
Published in: Rheumatology International 10/2010

01-08-2010 | Original Article

Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome

Authors: Gunter Assmann, Annette D. Wagner, Mueller Monika, Claudia Pfoehler, Michael Pfreundschuh, Wolfgang Tilgen, Klaus Roemer

Published in: Rheumatology International | Issue 10/2010

Login to get access

Abstract

Psoriasis (Ps), psoriatic arthritis (PsA), and SAPHO syndrome are diseases of unknown etiology that share common clinical features; however, family studies support the hypothesis of a genetic background for each of these diseases. To study the two common single-nucleotide polymorphisms (SNP) in the murine-double-minute-2-(Mdm2) and p53 genes in patients with Ps, PsA, and SAPHO syndrome. Genomic DNA was obtained from 187 patients with Ps, 50 with PsA, and 36 with SAPHO as well as 478 healthy controls. Mdm2-gene SNP T309G and p53-gene SNP G72C genotypes were determined by the polymerase chain reaction. Genotype and allele frequencies were analyzed with χ2-tests. Among the patients with Ps and PsA, no differences in allele or genotype frequencies of the p53-gene SNP G72C and Mdm2-gene SNP T309G were detected. However, in the SAPHO patients group, the frequencies of the Mdm2 SNP309 G allele and the genotype SNP 309 GG were significantly increased compared with the controls (G allele: 51.4 vs. 38.7%, P = 0.034; genotype GG: 36.1 vs. 14.2%, P = 0.002). In addition, the frequencies of the p53 SNP72 C allele and the genotype SNP 72 CC were also increased in the SAPHO patients cohort (C allele: 36.1 vs. 25.6%, P = 0.05; genotype CC: 16.7 vs. 6.3%, P = 0.05). SAPHO syndrome may be linked to an imbalance between MDM2 and p53 regulation with a “weak” p53-response associated with the Mdm2 SNP 309 G allele. In contrast, the p53 network does not seem to play a major role in pathogenesis of Ps or PsA.
Literature
1.
go back to reference Hannuksela-Svahn A, Pääkkö P, Autio P et al (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79:195–199CrossRefPubMed Hannuksela-Svahn A, Pääkkö P, Autio P et al (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79:195–199CrossRefPubMed
2.
go back to reference Salvador G, Sanmarti R, Garcia-Peiró A et al (2005) p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. Ann Rheum Dis 64:183–187CrossRefPubMed Salvador G, Sanmarti R, Garcia-Peiró A et al (2005) p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. Ann Rheum Dis 64:183–187CrossRefPubMed
3.
go back to reference Chamot AM, Benhamou CL, Kahn MF et al (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rhum Mal Osteoartic 54:187–196PubMed Chamot AM, Benhamou CL, Kahn MF et al (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rhum Mal Osteoartic 54:187–196PubMed
4.
go back to reference Schilling F, Kessler S (2000) SAPHO syndrome: clinico-rheumatologic and radiologic differentiation and classification of a patient sample of 86 cases. Z Rheumatol 59:1–28CrossRefPubMed Schilling F, Kessler S (2000) SAPHO syndrome: clinico-rheumatologic and radiologic differentiation and classification of a patient sample of 86 cases. Z Rheumatol 59:1–28CrossRefPubMed
6.
go back to reference Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16:67–72CrossRef Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16:67–72CrossRef
7.
go back to reference Bond GL, Hu W, Bond EE, Robins H et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell 119:591–602CrossRefPubMed Bond GL, Hu W, Bond EE, Robins H et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell 119:591–602CrossRefPubMed
8.
go back to reference Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed
9.
go back to reference Wright V, Moll JMH (1976) In: Seronegative Polyarthritis. North Holland Publishing Company, Amsterdam Wright V, Moll JMH (1976) In: Seronegative Polyarthritis. North Holland Publishing Company, Amsterdam
10.
go back to reference Assmann G, Wieczorek S, Wibisono D et al (2008) The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener`s granulomatosis. Clin Exp Rheumatol 26:72–75 Assmann G, Wieczorek S, Wibisono D et al (2008) The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener`s granulomatosis. Clin Exp Rheumatol 26:72–75
11.
go back to reference Butt C, Peddle L, Greenwood C et al (2006) Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case–control study. Arthritis Res Ther 8:R27CrossRefPubMed Butt C, Peddle L, Greenwood C et al (2006) Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case–control study. Arthritis Res Ther 8:R27CrossRefPubMed
12.
go back to reference Gladman DD, Rahman P, Krueger GG et al (2008) Clinical and genetic registries in psoriatic disease. J Rheumatol 35:1458–1463PubMed Gladman DD, Rahman P, Krueger GG et al (2008) Clinical and genetic registries in psoriatic disease. J Rheumatol 35:1458–1463PubMed
13.
go back to reference Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64:ii37–ii39CrossRefPubMed Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64:ii37–ii39CrossRefPubMed
14.
go back to reference Dumolard A, Gaudin P, Juvin R et al (1999) SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford) 38:463–467CrossRef Dumolard A, Gaudin P, Juvin R et al (1999) SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford) 38:463–467CrossRef
15.
go back to reference Queiro R, Moreno P, Sarasqueta C et al (2008) Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 26:125–128PubMed Queiro R, Moreno P, Sarasqueta C et al (2008) Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 26:125–128PubMed
16.
go back to reference Momand J, Wu HH, Dasgupta G (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15–29CrossRefPubMed Momand J, Wu HH, Dasgupta G (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15–29CrossRefPubMed
17.
go back to reference Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chemistry 282:32603–32612CrossRef Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chemistry 282:32603–32612CrossRef
Metadata
Title
Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome
Authors
Gunter Assmann
Annette D. Wagner
Mueller Monika
Claudia Pfoehler
Michael Pfreundschuh
Wolfgang Tilgen
Klaus Roemer
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1136-8

Other articles of this Issue 10/2010

Rheumatology International 10/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.